Belite Bio to present DRAGON Phase 3 tinlarebant data at Euretina
Belite Bio (NASDAQ: BLTE) is set to present topline results from its Phase 3 DRAGON study of tinlarebant in adolescent Stargardt disease type 1 (STGD1) at the Euretina congress in Vienna on 4 October 2026. The presentation will be delivered by Michel Michaelides of Moorfields Eye Hospital and UCL Institute of Ophthalmology, a senior clinical investigator rather than a company executive, lending it additional independent weight.
The company's chief medical officer, Hendrik Scholl, will also deliver a company overview at the affiliated Euretina Innovation Spotlight on 30 September, covering Belite Bio's broader pipeline in degenerative retinal diseases.
The DRAGON study and regulatory timeline
Tinlarebant is an oral small-molecule therapy that lowers serum retinol binding protein 4 (RBP4), the transport protein responsible for delivering retinol from the liver to the eye. By reducing retinol supply to the retina, it curtails the formation of bisretinoids, the toxic by-products of the visual cycle that accumulate in STGD1 and drive progressive loss of central vision. The company has said the DRAGON Phase 3 trial met its primary endpoint, though it has not released the full dataset ahead of the Euretina presentation.
Clinically, the stakes are substantial. There are currently no approved treatments for STGD1, which is the most common inherited macular dystrophy and is caused by mutations in the retina-specific ABCA4 gene. Tinlarebant has already secured Breakthrough Therapy Designation, Fast Track Designation, and Rare Pediatric Disease Designation from the FDA, alongside orphan drug status in the US, Europe, Japan, and Switzerland.
The FDA accepted Belite Bio's new drug application for tinlarebant in August 2026 under priority review, setting a Prescription Drug User Fee Act date of 12 February 2027. A positive decision would make tinlarebant the first approved therapy for STGD1.
Market context and competitive landscape
The inherited retinal disease space has attracted growing investment over the past decade, in large part because regulatory frameworks for rare and orphan conditions offer incentivised pathways. Spark Therapeutics' voretigene neparvovec (Luxturna), approved for RPE65-mutation-associated dystrophy, was the first gene therapy approved for an inherited retinal disease in the US, establishing a precedent for regulatory engagement in this category. However, gene therapy approaches to STGD1 have proved technically challenging given the large size of the ABCA4 gene. Tinlarebant's oral, small-molecule mechanism side-steps that barrier entirely.
Belite Bio also has a Phase 2/3 DRAGON II trial running in adult and adolescent STGD1 subjects and a separate Phase 3 PHOENIX trial in geographic atrophy, a larger patient population in advanced dry age-related macular degeneration. Positive data from either of those programmes could significantly extend the commercial opportunity beyond STGD1.
Investors and clinicians attending Euretina will be scrutinising the full DRAGON dataset for effect size on retinal degeneration endpoints, safety signals, and evidence of benefit across age subgroups. With the PDUFA date less than five months away, the Vienna presentation is one of the final chances for the field to evaluate the evidence base before an FDA advisory committee process, if one is convened.